Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Grifols SA Stock , GIFLF

8.75 EUR -0.14 -1.52%
Official Close 3/17/2023 STU
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Grifols Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Grifols Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell

Grifols Estimates* in EUR

  2023 2024 2025 2026 2027
Revenue 6,620 7,152 7,790 8,334 8,801
Dividend 0.05 0.16 0.42 0.46 0.70
Dividend Yield (in %) 0.48 % 1.61 % 4.19 % 4.55 % 6.95 %
EPS 0.65 1.10 1.47 1.73 1.93
P/E Ratio 13.58 8.03 6.03 5.14 4.59
EBIT 1,030 1,439 1,728 1,918 2,012
EBITDA 1,475 1,862 2,141 2,390 2,507
Net Profit 375 707 921 1,132 1,249
Net Profit Adjusted 471 763 1,062 1,202 1,269
Pre-Tax Profit 562 972 1,295 1,517 1,590
Net Profit (Adjusted) 590 928 1,063 - -
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 0.56 1.03 1.40 1.41 1.75
Gross Income 2,597 3,021 3,316 3,568 3,761
Cash Flow from Investing -375 -446 -415 -486 -425
Cash Flow from Operations 898 1,107 1,265 1,591 1,714
Cash Flow from Financing 169 -317 -459 -399 -2,444
Cash Flow per Share 1.45 1.60 2.06 2.81 -
Free Cash Flow 578 754 911 1,124 1,076
Free Cash Flow per Share 0.67 0.97 0.83 - -
Book Value per Share 11.11 12.13 14.55 13.70 -
Net Debt 9,652 9,080 8,092 7,263 5,565
Research & Development Exp. 398 427 465 510 469
Capital Expenditure 337 357 416 526 -
Selling, General & Admin. Exp. 1,056 1,077 1,115 1,272 1,475
Shareholder’s Equity 7,443 8,127 9,018 10,953 10,745
Total Assets 21,844 22,278 23,155 23,752 22,446
  Previous Quarter
ending 12/31/22 		Current Quarter Next Quarter Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 1 1 1 17 17
Average Estimate 0.060 EUR 0.230 EUR 0.240 EUR 0.653 EUR 1.104 EUR
Year Ago - - 0.130 EUR - 0.653 EUR
Publish Date 2/28/2023 5/4/2023 7/27/2023 - -
Revenue Estimates
No. of Analysts 5 - - 16 16
Average Estimate 1,595 EUR - - 6,620 EUR 7,152 EUR
Year Ago - - - 6,064 EUR 6,620 EUR
Publish Date 2/28/2023 - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Grifols Dividend Calendar

Date Name Dividend *yield Currency
2022 Grifols SA - - EUR
2021 Grifols SA - - EUR
2020 Grifols SA 0.30 1.24 EUR
2019 Grifols SA 0.29 0.93 EUR
2018 Grifols SA 0.28 1.22 EUR
2017 Grifols SA 0.31 1.27 EUR
2016 Grifols SA 0.26 1.35 EUR
2015 Grifols SA 0.35 1.64 EUR
2015 Grifols SA 0.25 1.16 EUR
2014 Grifols SA 0.28 1.69 EUR
2014 Grifols SA 0.22 1.31 EUR
2013 Grifols SA 0.20 1.15 EUR
2013 Grifols SA 0.18 1.03 EUR
2012 Grifols SA - - EUR
2011 Grifols SA - - EUR
2010 Grifols SA - - EUR
2009 Grifols SA 0.11 1.88 EUR
2009 Grifols SA 0.14 2.30 EUR
2008 Grifols SA 0.12 1.95 EUR
2007 Grifols SA 0.06 0.78 EUR
*Yield of the Respective Date

Grifols SA Calendar

Event Estimate Info Date
Earnings Report 0.230 EUR Q1 2023 Earnings Release 05/04/2023
Earnings Report 0.240 EUR Q2 2023 Earnings Release 07/27/2023
Earnings Report - Q3 2023 Earnings Release 11/08/2023
Earnings Report - Q1 2024 Earnings Release 05/02/2024

Grifols SA Past Events

Event Actual EPS Info Date
Earnings Report 0.130 EUR Q4 2022 Earnings Release 02/28/2023

Grifols Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
5
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Grifols Shareholder

Owner in %
Freefloat 69.10
Grifols Roura Family 9.20
Scranton Enterprises BV 8.13
Grifols Gras Family 7.09
American Funds EuroPacific Growth Fund 4.23
Government Pension Fund - Global (The) 2.33
Hardman Johnston Global Equity 1.48
American Funds New Perspective Fund 1.33
Vanguard Total International Stock Index Fund 0.99
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Grifols Management

Name Job
Lafmin Morgan Chief Commercial Officer
David Ian Bell Chief Development Officer & General Counsel
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Montserrat Gaja Llamas Chief Human Resources Officer
Daniel Fleta Coit Chief Industrial Officer
Xavier Sueiras Gil Chief Information Technology Officer
Marilyn Rosa-Bray Chief Medical Officer & SVP-Global Plasma Quality
Vicente Blanquer Torre Chief Quality Officer
Victor Grifols Deu Co-Chief Executive Officer & Executive Director
Steven F. Mayer Director
Thomas Heinrich Glanzmann Executive Chairman
Tomás Dagá Gelabert External Director & Vice Secretary
Víctor Grifols Roura Honorary Chairman
Susana González Rodríguez Independent Director
Iñigo Sánchez-Asiaín Mardones Independent Director
James Costos Independent Director
Enriqueta Felip Font Independent Director
Montserrat Muñoz Abellana Independent Director
Carina Szpilka Lázaro Lead Independent Director
Antonio Martínez Martínez President-Diagnostic Scientific & Research
Nuria Martín Barnés Secretary
Montserrat Lloveras Calvo VP, Director-Corporate Accounting & Reporting
Nuria Pascual Lapeña VP-Corporate Treasury & Investor Relations
Raimon Grifols Roura Vice Chairman & Co-Chief Executive Officer
Fernando Sebastian Rodriguez Haro Vice President-Corporate Planning & Control